VAP-1 INHIBITORS FOR TREATING PAIN
This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.
1 .- 2 . (canceled)
3 . A method for the treatment of pain, which comprises administering to a subject suffering from pain an effective amount of a VAP-1 inhibitor.
4 . A method for the treatment of pain according to claim 3 , which comprises administering to a subject suffering from pain an effective amount of a VAP-1 inhibitor,
PROVIDED THAT
the VAP-1 inhibitor is other than (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof.
5 . A method for the treatment of pain according to claim 3 , wherein the method comprises administering to a subject suffering from pain an effective amount of a pharmaceutical composition which comprises: the VAP-1 inhibitor; and a pharmaceutically acceptable carrier, excipient, or diluent.
6 . A method for the treatment of pain according to claim 5 , wherein the VAP-1 inhibitor is other than (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof.
7 . A method according to claim 3 , wherein the VAP-1 inhibitor has the structure of any one of the specific Examples of VAP-1 inhibitor compounds, polypeptides or proteins disclosed herein.
8 . A method according to claim 3 , wherein the VAP-1 inhibitor is a compound selected from 1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazin-1-yl)ethan-1-one, 1-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-4-methanesulfonylpiperazine, 4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine, (S)-carbidopa, benserazide, LJP1207, BTT1023, RTU-1096, PXS4728 and ASP8232 or a hydrate or pharmaceutically acceptable salt thereof.
9 . A method according to claim 3 , wherein the VAP-1 inhibitor is (S)-carbidopa, or a hydrate or a pharmaceutically acceptable salt thereof.
10 .- 11 . (canceled)
12 . A method according to claim 3 , wherein the pain is inflammatory pain.
13 . A method according to claim 3 , wherein the pain is neuropathic pain.
14 . (canceled)
15 . A method for the treatment of pain according to claim 3 , which comprises administering to a subject suffering from pain an effective amount of a VAP-1 inhibitor and an effective amount of a steroid.
16 . (canceled)
17 . A method according to claim 15 , wherein the VAP-1 inhibitor has the structure of any one of the specific Examples of VAP-1 inhibitor compounds, polypeptides or proteins disclosed herein.
18 . A method according to claim 15 , wherein the VAP-1 inhibitor is a compound selected from 1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazin-1-yl)ethan-1-one, 1-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-4-methanesulfonylpiperazine, 4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine, (S)-carbidopa, benserazide, LJP1207, BTT11023, RTU-1096, PXS4728 and ASP8232, or a hydrate or a pharmaceutically acceptable salt thereof, and combinations thereof.
19 . A method according to claim 15 , wherein the VAP-1 inhibitor is (S)-carbidopa, or a hydrate or a pharmaceutically acceptable salt thereof.
20 . A method according to claim 15 , or a pharmaceutical composition for use according to claim wherein the pain is inflammatory pain.
21 . A method according to claim 15 , wherein the pain is neuropathic pain.
22 . A method according to claim 15 , wherein the steroid is a glucocorticoid.
23 . A method according to claim 15 , wherein the steroid is selected from any one of prednisone, prednisolone, methyl prednisolone, triamcinolone, dexamethasone, hydrocortisone, deflazacort, betamethasone and budenoside, and combinations thereof.
24 . A combined preparation, which comprises: (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof; and a steroid.
25 . A method of treating pain comprising administering to a subject suffering from pain an effective amount of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-51H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof, and an effective amount of a steroid.
26 . A pharmaceutical composition, which comprises: (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate or a hydrate or a pharmaceutically acceptable salt thereof; a steroid; and a pharmaceutically acceptable carrier, excipient, or diluent.
27 .- 29 . (canceled)
30 . A method according to claim 25 , wherein the steroid is a glucocorticoid.
31 . A method according to claim 30 , wherein the steroid is selected from any one of prednisone, prednisolone, methyl prednisolone, triamcinolone, dexamethasone, hydrocortisone, deflazacort, betamethasone and budenoside.
32 . A method according to claim 3 , wherein the pharmaceutically acceptable salt is the mesylate salt.
33 . A method according to claim 3 , wherein the pharmaceutically acceptable salt is the sulphate salt, or a hydrate thereof.
34 . A method of treatment according to claim 3 , wherein the treatment is treatment in a human subject.